With 1 million new cases and 200,000 children dead each year, Tuberculosis (TB) is now the leading cause of death from infectious diseases for children of all ages globally (UNICEF). ImproViTB is among the first pediatric clinical studies in the Central African region aimed at improving the clinical outcome and quality of life of children with pulmonary tuberculosis through a standard antituberculosis treatment supplemented with vitamin D.
This project is lead by a consortium of research institutions and universities from 4 Central African countries (Republic of Congo, Democratic Republic of Congo, Cameroon and Gabon) and 3 European countries, coordinated by CANTAM (Prof. Francine Ntoumi), the Network of Excellence in clinical research for Central African region.

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

A multidisciplinary consortium of African and European researchers responded to the urgent call from the European Union by developing a research project on the current Monkeypox outbreak in central Africa.

The spread of Mpox virus (MPXV) in Sub-Saharan Africa, specifically Democratic Republic of Congo (DRC) and Republic of Congo (RoC) presents an urgent public health concern with global implications. MPXV cases

The COVID-19 pandemic threatens to reverse recent progress in reducing the global burden of Tuberculosis

The COVID-19 pandemic threatens to reverse recent progress in reducing the global burden of tuberculosis. The global number of deaths for tuberculosis could increase by around 200.000–400.000 in 2020 alone,

Second European-African training for the Congolese team on “SARS-CoV-2 detection by ApoH enzyme”

As part of the implementation of ITAIL-COVID-19 project funded by the European Development Countries Partnership for Clinical Trials (EDCTP) and coordinated by the Congolese Foundation for Medical Research (FCRM), the